Endorsers

GlaxoSmithKline

Sector in which the organization works:

Pharmaceutical

Short description of the organization and its work to control and eliminate NTDs

In support of the London NTD Declaration goals, GlaxoSmithKline (GSK) expanded its significant albendazole donation programme which targets two neglected diseases and has strengthened its commitment to support R&D efforts. GSK pledged to extend by an additional five years its commitment to donate 400 million albendazole tablets each year to the WHO to enable de-worming of school age children in all endemic countries. Expanding this programme, which was initially planned to run to 2015, will equate to an additional two billion tablets of albendazole being donated up to 2020.

GSK has also reaffirmed its commitment to supply all the albendazole needed to eliminate lymphatic filariasis worldwide by 2020. GSK currently donates 600 million tablets of albendazole each year to WHO to prevent transmission of lymphatic filariasis and has donated over two billion doses to the WHO to date. During 2000 to 2010, GSK donated over 2.6 billion albendazole treatments to 58 countries. The overall economic benefit of the lymphatic filariasis programme during 2000-2007 is conservatively estimated at US$ 24 billion.

GSK will continue to play an open and active role in developing new and better treatments for NTDs through collaborative partnerships such as with the Drugs for Neglected Diseases initiative (DNDi), a not-for-profit R&D organisation. GSK shares knowledge, research and intellectual property with groups such as DNDi to support drug discovery efforts against diseases including sleeping sickness, visceral leishmaniasis and Chagas. GSK is also a founder member of the WIPO Re:Search consortium created to help accelerate the development of new and better treatments against NTDs.

In addition, GSK continues to invest in its own active R&D programme for diseases that most affect developing countries, including NTDs. This R&D portfolio currently includes projects for Chagas, dengue, human African trypanosomiasis and leishmaniasis.

Notes:

  • Lymphatic filariasis (LF): GSK has pledged to donate albendazole for as long as necessary until the disease is eliminated; best estimates put the scale of this commitment at around six billion treatments. Under our current commitment we donate 600 million tablets each year to the WHO to support efforts to eliminate lymphatic filariasis. In addition to donating free albendazole tablets, we provide significant financial support for coalition-building, workshops and communications, and dedicated staff expertise.
  • Soil-transmitted helminths: In September 2011, GSK formalised a commitment with WHO to donate 400 million tablets of albendazole each year to treat school age children at risk of intestinal worms.
  • R&D for NTDs: GSK has a specific R&D group focused on diseases of the developing world, including NTDs. Its R&D portfolio already includes projects for a number of diseases of particular relevance to developing countries including: bacterial meningitis, Chagas disease, chlamydia, dengue, HIV/AIDS, human African trypanosomiasis, leishmaniasis, malaria, pandemic influenza, pneumococcal disease and TB. GSK has established an R&D centre in Tres Cantos, Spain dedicated to research for NTDs, malaria and tuberculosis (TB) where researchers from external organisations and academic centres work alongside GSK scientists as part of an Open Lab initiative. So far, within the Open Lab, 11 scientists have worked on seven projects at the campus. Among the projects underway are research to identify and optimise compounds that could be tested in humans against multi-drug resistant TB, three separate projects into malaria, including one that investigates potential compounds from the GSK chemical library, and a new approach against the parasites that can cause leishmaniasis.

GSK continues to invest in vaccine research against diseases of the developing world. The company has been working on a malaria vaccine for more than two decades. Positive first results from the phase III study of GSK’s candidate vaccine, RTS,S, being developed in partnership with the PATH Malaria Vaccine Initiative (MVI), were announced in October 2011. 

In October 2011, GSK joined WIPO Re:Search as a founding member. WIPO Re:Search is an evolution of GSK’s Pool for Open Innovation against Neglected Tropical Diseases (POINT). It brings together eight leading pharmaceutical companies in collaboration with the US National Institutes of Health (NIH) and multiple non-profit research organizations under the auspices of WIPO – a UN body – to help accelerate the development of new and better treatments against NTDs.

AGSK has a number of initiatives aimed at increasing access to medicines in the poorest countries in the world, including the creation of the Developing Countries and Market Access (DCMA) unit in 2010. In least developed countries (LDCs), where many people survive on less than US$1 a day, GSK caps the prices of GSK patented medicines and vaccines at no more than 25% of developed world prices and reinvests 20% of profits back into projects that strengthen healthcare infrastructure in these countries. GSK has a long-standing tiered pricing policy for vaccines which enables poorer countries to pay significantly less than higher income countries for the same vaccine with the lowest prices for agencies such as UNICEF which purchase large volumes of vaccines for the world’s poorest children. GSK vaccines are included in immunisation campaigns in 182 countries worldwide and 1.4 billion vaccine doses were delivered in 2010, of which nearly 1 billion were shipped for use in developing countries.

For more on GSK’s commitment to the developing world, visit our website http://www.gsk.com/media/developing-world.htm

GlaxoSmithKline is one of the 20 original endorsers of the London Declaration

Program Email

andy.l.wright@gsk.com